Drug combination for treatment of gastric cancer
A gastric cancer therapy dosing regimen that results in enhanced therapeutic effectiveness and reduced side effects has been discovered. Gastric cancer patients treated daily with a combination of minnelide prodrug and paclitaxel experienced significant negative side effects and progression of the cancer. A minnelide prodrug and paclitaxel combination therapy administered according to a novel dosing regimen provided significantly improved treatment results. The novel dosing regimen comprises a 28-day cycle wherein minnelide prodrug was dosed once per day on days 1 to 5, 8 to 12, and 15 to 19 of the cycle, and paclitaxel was dosed once per day on days 1, 8, and 15 of the cycle. The novel dosing regimen was shown to be both effective toward treating gastric cancer and was well tolerated in human patients.
1. A method for treating gastric cancer in a cancer patient, the method comprising administering to a gastric cancer patient during a 28 day cycle a therapeutically effective combination of:
a) about 0.25 mg to about 2.0 mg of minnelide according to a first regimen wherein a dose is given once per day on days 1 to 5, 8 to 12, and 15 to 19 of the cycle; and
b) about 60 mg/m 2 to about 100 mg/m 2 of paclitaxel according to a second regimen wherein a dose is given once per day on days 1, 8, and 15 of the cycle;
wherein the 28-day cycle is repeated one or more times and the combination effectively treats the gastric cancer.
2. The method of claim 1 wherein the cancer patient is administered about 0.5 mg to about 1.25 mg of minnelide according to the first regimen.
3. The method of claim 1 wherein the cancer patient is administered about 0.75mg to about 1.25 mg of minnelide according to the first regimen and about 60 mg/m 2 to about 80 mg/m 2 of paclitaxel according to the second regimen.
4. The method of claim 1 wherein the cancer patient is administered about 0.75 mg of minnelide according to the first regimen and about 80 mg/m 2 of paclitaxel according to the second regimen.
5. The method of claim 1 wherein the cancer patient is administered about 1.0 mg of minnelide according to the first regimen and about 80 mg/m 2 of paclitaxel according to the second regimen.
6. The method of claim 1 wherein the cancer patient is administered about 1.25mg of minnelide according to the first regimen and about 80 mg/m 2 of paclitaxel according to the second regimen.
7. The method of claim 1 wherein the cancer patient is administered about 1.5 mg of minnelide according to the first regimen and about 80 mg/m 2 of paclitaxel according to the second regimen.
8. The method of claim 1 wherein the cancer patient has been diagnosed with advanced gastric cancer.
9. The method of claim 1 wherein the cancer patient has tumors that continued to progress after receiving paclitaxel chemotherapy.
10. The method of claim 1 wherein cancer tumors of the cancer patient are reduced in diameter by 30% or greater after five or more 28-day cycles.
11. The method of claim 1 wherein minnelide is administered orally and paclitaxel is administered intravenously.
12. The method of claim 1 wherein the patient is further suffering from breast cancer, bladder cancer, liver cancer, lung cancer, ovarian cancer, skin cancer, or a combination thereof, and the method effectively treats the cancer patient.
13. The method of claim 1 wherein the combination effectively treats the gastric cancer without causing a complete blood count of the cancer patient to lower by more than 25% from baseline.
14. The method of claim 1 wherein the combination effectively treats the gastric cancer without causing a platelet count or an absolute neutrophil count in the cancer patient to lower by more than 25% from baseline.
15. A method for treating advanced gastric cancer in a cancer patient wherein the cancer continued to progress after paclitaxel chemotherapy, the method comprising administering to the cancer patient diagnosed with advanced gastric cancer during a 28 day cycle a therapeutically effective combination of:
a) about 0.5 mg to about 1.5 mg of minnelide administered orally according to a first regimen wherein a dose is given once per day on days 1 to 5, 8 to 12, and 15 to 19 of the cycle; and
b) about 70 mg/m 2 to about 90 mg/m 2 of paclitaxel administered intravenously according to a second regimen wherein a dose is given once per day on days 1, 8, and 15 of the cycle;
wherein the 28-day cycle is repeated two or more times, thereby achieving disease stability or disease regression of the advanced gastric cancer.